In part 2 of this video series, David Ilson, MD, PhD, discusses approvals and advancements in the immunotherapy space for GEJ/GI cancer.

In part 2 of this series, Andrea Cercek, MD, discusses the clinical findings, molecular drivers/alterations, and further research for "Early On-Set Colorectal Cancer: A Biologically Distinct Threat…

In part 1 of this video series, Andrea Cercek, MD, discusses the background and possible association of hereditary/environmental factors in early-onset CRC.

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results…

William Harris, MD, discusses a feasibility study on using biospecimen-based multi-platform profiling for patients with resected biliary tract cancer.

Adam Diehl, MD, discusses an ongoing study assessing the ability to obtain NGS, ctDNA monitoring, and organoid drug sensitivity screening in patients with resected localized biliary tract cancer.

Gentry King, MD, discusses an ongoing feasibility study on multiomic platform‑based testing in patients with localized and resectable biliary tract cancers.

Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and discusses new advancements in the treatment of HER2+ gastric cancer.